Share Article
At Gilead, the mission has always been grounded in a belief that science can—and must—deliver for people facing the world’s most serious diseases. For nearly 40 years, the company has pursued bold ideas, taken on urgent public health challenges, and worked to ensure breakthroughs reach the people who need them most.
Gilead’s 2025 Responsible Business and Impact Report reflects how that mission comes to life today. It tells the story of a company advancing next generation innovation, expanding access at unprecedented speed, empowering people and communities, and embedding sustainability across our operations.
“Gilead's 17,000-plus employees worldwide are driving all of our achievements with the intrinsic motivation of making the world a better, healthier place,” says Daniel O’Day, Chairman and Chief Executive Officer. “Together with our partners, from nonprofit organizations and government agencies to voluntary licensees and healthcare providers we are all working to make a positive contribution to healthcare and society as a whole.”
As the global health landscape grows more complex, responsible business has never been more central to how we operate.
Driving the next wave of scientific innovation
Gilead is known to take on the most serious diseases and stay the course. In 2025, that determination delivered a historic first: FDA approval of the world’s first twice yearly HIV prevention option, decades in the making. Today, more than 50 clinical stage programs are advancing potential breakthroughs across virology, oncology and inflammation—the most robust pipeline in company history. In oncology, Gilead is focused on hard to treat cancers, including metastatic triple negative breast cancer and blood cancers, while expanding the horizons of potential curative cell therapies through Kite. In inflammation, innovative therapies help address significant unmet needs for people living with rare autoimmune diseases. Together, these efforts reflect a defining characteristic of Gilead: meaningful public health progress demands persistence.
Expanding access and delivering exponential impact
At Gilead, access is also engineered into every step of development, approval, and delivery. In 2025, that approach came to life through the global rollout of the aforementioned twice-yearly HIV prevention medication. The company sought voluntary licenses across 120 low and lower middle income countries and partnerships with leading global health organizations, along with early no profit supply strategies to meet the urgent need. Notably, this became the first new HIV prevention medicine to be made available in a resource limited country within the same calendar year it launched in the U.S. Separately, through Gilead’s public health and community initiatives, such as FOCUS, we are strengthening health systems at scale by enabling partners to embed routine screening and linkage to care for HIV, hepatitis B and hepatitis C. Since its launch in 2010, FOCUS partners have supported millions of screenings in underserved communities, helping normalize early diagnosis, reduce stigma and connect people to care . The result accelerates progress toward global public health goals.
Empowering people and communities
Behind every breakthrough at Gilead is a global workforce united by purpose. In 2025, Gilead continued investing in an inclusive, high performing employee experience: one that empowers employees to grow, innovate, and lead with integrity. Investments in AI enabled tools, expanded learning platforms and leadership development are reshaping how work gets done—breaking down silos and unlocking new ways to collaborate across science and business. The company’s philanthropic arm, the Gilead Foundation and corporate giving programs invested $260M+ in 2025, supporting efforts that address the social determinants of health, from STEM education and healthcare workforce pathways to food security and community resilience. Through employee volunteerism and local partnerships, Gilead continues to strengthen the communities where our employees live and work.
Advancing environmental sustainability
Health and sustainability are inseparable. Our sustainability strategy is grounded in science based targets and strong governance, with a clear focus on reducing emissions, conserving water, minimizing waste and designing more sustainable laboratories and manufacturing facilities. In 2025, Gilead made significant progress against its environmental goals, including achieving ~100% renewable electricity in global operations and zero waste to landfill at our Foster City headquarters. From award winning energy efficient labs to biodiversity focused campus redesigns, environmental stewardship is increasingly embedded into how Gilead builds for the future.
Looking ahead
Today, Gilead is recognized as an engine of innovation, a driver of patient impact, and a responsible business committed to long term value creation. Our 2025 Responsible Business and Impact Report reinforces a simple truth about who we are: at Gilead, what’s next is being delivered now.
Read the full 2025 Responsible Business and Impact Report here.